Tissue-type plasminogen activator is not necessary for platelet-derived growth factor-c activation

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 2, 2014, Pages 318-325

  Riehle, Kimberly J ^a   Johnson, Melissa M ^a,c   Johansson, Fredrik ^a   Bauer, Renay L ^a   Hayes, Brian J ^a   Gilbertson, Debra G ^b   Haran, Aaron C ^b,d   Fausto, Nelson ^a   Campbell, Jean S ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d GILEAD SCIENCES INC   (United States)

Author keywords

Liver fibrosis; Plasminogen activator; Platelet derived growth factor

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR C; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HEPATOMEGALY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER FIBROSIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SPLENOMEGALY;

BRDU; BROMODEOXYURIDINE; COMPLEMENT SUBCOMPONENTS CLR/CLS, UEGF, BMP1; CUB; ECM; EXTRACELLULAR MATRIX; H&E; HCC; HEMATOXYLIN & EOSIN; HEPATOCELLULAR CARCINOMA; INTRAPERITONEALLY; IP; KNOCK-OUT; KO; LIVER FIBROSIS; NON-PARENCHYMAL CELL; NPC; PAI-1; PDGF; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR-1; PLATELET-DERIVED GROWTH FACTOR; TG; TISSUE-TYPE PLASMINOGEN ACTIVATOR; TPA; TRANSGENIC; UPA; UROKINASE PLASMINOGEN ACTIVATOR;

ANIMALS; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; HEPATOCYTES; HUMANS; LIVER; LIVER CIRRHOSIS; LYMPHOKINES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET-DERIVED GROWTH FACTOR; PROTEOLYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84890881523     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.11.013     Document Type: Article

References (31)

1. Ghosh A.K., Vaughan D.E. PAI-1 in tissue fibrosis. J. Cell. Physiol. 2012, 227:493-507.
2. Zorio E., Gilabert-Estelles J., Espana F., Ramon L.A., Cosin R., Estelles A. Fibrinolysis: the key to new pathogenetic mechanisms. Curr. Med. Chem. 2008, 15:923-929.
3. Irigoyen J.P., Munoz-Canoves P., Montero L., Koziczak M., Nagamine Y. The plasminogen activator system: biology and regulation. Cell Mol. Life Sci. CMLS 1999, 56:104-132.
4. Kang L.I., Mars W.M. Fibrinolytic factors in liver fibrosis. Curr. Pharm. Biotechnol. 2011, 12:1441-1446.
5. Carmeliet P., Schoonjans L., Kieckens L., Ream B., Degen J., Bronson R., De Vos R., van den Oord J.J., Collen D., Mulligan R.C. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994, 368:419-424.
6. Bezerra J.A., Currier A.R., Melin-Aldana H., Sabla G., Bugge T.H., Kombrinck K.W., Degen J.L. Plasminogen activators direct reorganization of the liver lobule after acute injury. Am. J. Pathol. 2001, 158:921-929.
7. Fredriksson L., Li H., Eriksson U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev. 2004, 15:197-204.
8. Olson L.E., Soriano P. Increased PDGFRalpha activation disrupts connective tissue development and drives systemic fibrosis. Dev. Cell 2009, 16:303-313.
9. Bonner J.A., Buchsbaum D.J., Rogers B.E., Grizzle W.E., Trummell H.Q., Curiel D.T., Fiveash J.B., Ove R., Raisch K.P. Adenoviral vector-mediated augmentation of epidermal growth factor receptor (EGFr) enhances the radiosensitization properties of anti-EGFr treatment in prostate cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58:950-958.
10. Wynn T.A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 2008, 214:199-210.
11. Gilbertson D.G., Duff M.E., West J.W., Kelly J.D., Sheppard P.O., Hofstrand P.D., Gao Z., Shoemaker K., Bukowski T.R., Moore M., Feldhaus A.L., Humes J.M., Palmer T.E., Hart C.E. Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor. J. Biol. Chem. 2001, 276:27406-27414.
12. Li X., Ponten A., Aase K., Karlsson L., Abramsson A., Uutela M., Backstrom G., Hellstrom M., Bostrom H., Li H., Soriano P., Betsholtz C., Heldin C.H., Alitalo K., Ostman A., Eriksson U. PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat. Cell Biol. 2000, 2:302-309.
13. Franke K., Curth K., Lenart J., Knochenhauer D., Kietzmann T. Enhanced plasminogen activator inhibitor-1 expression in transgenic mice with hepatocyte-specific overexpression of superoxide dismutase or glutathione peroxidase. Antioxid. Redox Signal. 2004, 6:721-728.
14. Fredriksson L., Li H., Fieber C., Li X., Eriksson U. Tissue plasminogen activator is a potent activator of PDGF-CC. EMBO J. 2004, 23:3793-3802.
15. Su E.J., Fredriksson L., Geyer M., Folestad E., Cale J., Andrae J., Gao Y., Pietras K., Mann K., Yepes M., Strickland D.K., Betsholtz C., Eriksson U., Lawrence D.A. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat. Med. 2008, 14:731-737.
16. Su E.J., Fredriksson L., Schielke G.P., Eriksson U., Lawrence D.A. Tissue plasminogen activator-mediated PDGF signaling and neurovascular coupling in stroke. J. Thromb. Haemost. 2009, 7(Suppl. 1):155-158.
17. Campbell J.S., Hughes S.D., Gilbertson D.G., Palmer T.E., Holdren M.S., Haran A.C., Odell M.M., Bauer R.L., Ren H.P., Haugen H.S., Yeh M.M., Fausto N. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:3389-3394.
18. Riehle K.J., Campbell J.S., McMahan R.S., Johnson M.M., Beyer R.P., Bammler T.K., Fausto N. Regulation of liver regeneration and hepatocarcinogenesis by suppressor of cytokine signaling 3. J. Exp. Med. 2008, 205:91-103.
19. Campbell J.S., Johnson M.M., Bauer R.L., Hudkins K.L., Gilbertson D.G., Riehle K.J., Yeh M.M., Alpers C.E., Fausto N. Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis. Differentiation 2007, 75:843-852.
20. Hudkins K.L., Gilbertson D.G., Carling M., Taneda S., Hughes S.D., Holdren M.S., Palmer T.E., Topouzis S., Haran A.C., Feldhaus A.L., Alpers C.E. Exogenous PDGF-D is a potent mesangial cell mitogen and causes a severe mesangial proliferative glomerulopathy. J. Am. Soc. Nephrol. JASN 2004, 15:286-298.
21. Gately S., Twardowski P., Stack M.S., Cundiff D.L., Grella D., Castellino F.J., Enghild J., Kwaan H.C., Lee F., Kramer R.A., Volpert O., Bouck N., Soff G.A. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:10868-10872.
22. Vaquero J., Campbell J.S., Haque J., McMahan R.S., Riehle K.J., Bauer R.L., Fausto N. Toll-like receptor 4 and myeloid differentiation factor 88 provide mechanistic insights into the cause and effects of interleukin-6 activation in mouse liver regeneration. Hepatology 2011, 54:597-608.
23. Torimura T., Ueno T., Kin M., Taniguchi E., Nakamura T., Inoue K., Sakata R., Hashimoto O., Sakamoto M., Ohira H., Kumashiro R., Sata M., Yano H., Kojiro M., Veitonmaki N., Cao Y. Gene transfer of kringle 1-5 suppresses tumor development and improves prognosis of mice with hepatocellular carcinoma. Gastroenterology 2006, 130:1301-1310.
24. Schmitz V., Wang L., Barajas M., Gomar C., Prieto J., Qian C. Treatment of colorectal and hepatocellular carcinomas by adenoviral mediated gene transfer of endostatin and angiostatin-like molecule in mice. Gut 2004, 53:561-567.
25. Zimmermann H.W., Koch A., Seidler S., Trautwein C., Tacke F. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis. Liver. Int. 2012, 32:500-509.
26. Zimmermann H.W., Reuken P.A., Koch A., Bartneck M., Adams D.H., Trautwein C., Stallmach A., Tacke F., Bruns T. Soluble urokinase plasminogen activator receptor is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality. J. Intern. Med. 2013.
27. Lee S.R., Guo S.Z., Scannevin R.H., Magliaro B.C., Rhodes K.J., Wang X., Lo E.H. Induction of matrix metalloproteinase, cytokines and chemokines in rat cortical astrocytes exposed to plasminogen activators. Neurosci. Lett. 2007, 417:1-5.
28. Hurst N.J., Najy A.J., Ustach C.V., Movilla L., Kim H.R. Platelet-derived growth factor-C (PDGF-C) activation by serine proteases: implications for breast cancer progression. Biochem. J. 2012, 441:909-918.
29. Lei H., Velez G., Hovland P., Hirose T., Kazlauskas A. Plasmin is the major protease responsible for processing PDGF-C in the vitreous of patients with proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 2008, 49:42-48.
30. Fredriksson L., Ehnman M., Fieber C., Eriksson U. Structural requirements for activation of latent platelet-derived growth factor CC by tissue plasminogen activator. J. Biol. Chem. 2005, 280:26856-26862.
31. Ehnman M., Li H., Fredriksson L., Pietras K., Eriksson U. The uPA/uPAR system regulates the bioavailability of PDGF-DD: implications for tumour growth. Oncogene 2009, 28:534-544.